Bimekizumab Clinical Trials (2026): 51 Studies for Psoriatic Arthritis & Chronic Plaque Psoriasis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
51 Bimekizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 17 indications (including Psoriatic Arthritis & Chronic Plaque Psoriasis) and 13,882 total planned enrollment. 24 Phase 3 Bimekizumab trials and 14 Phase 2, 5 Phase 4 are listed. 11 Bimekizumab clinical trials are actively recruiting at 44 U.S. sites across 19 states. Most recent activity: NCT06425549 (Nov 2030).
Where to Participate: All Bimekizumab Trial Sites in the U.S. (44 sites across 19 states)
Every actively recruiting Bimekizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | UCB Biopharma SRL Investigator Site #114 | Peoria85381-5025 | NCT07290036 | Map |
| AZ | UCB Biopharma SRL Investigator Site #50175 | Phoenix85006 | NCT06921850 | Map |
| CA | UCB Biopharma SRL Investigator Site #127 | Apple Valley92307 | NCT07290036 | Map |
| CA | UCB Biopharma SRL Investigator Site #111 | Covina91722 | NCT07290036 | Map |
| CA | UCB Biopharma SRL Investigator Site #117 | Riverside92518 | NCT07290036 | Map |
| CA | UCB Biopharma SRL Investigator Site #50708 | Roseville95661 | NCT06921850 | Map |
| CA | UCB Biopharma SRL Investigator Site #125 | San Leandro94578 | NCT07290036 | Map |
| CA | UCB Biopharma SRL Investigator Site #105 | Santa Monica90404 | NCT06888193 | Map |
| CA | UCB Biopharma SRL Investigator Site #126 | Temecula92592 | NCT07290036 | Map |
| CA | UCB Biopharma SRL Investigator Site #141 | Upland91786 | NCT07290036 | Map |
| CA | UCB Biopharma SRL Investigator Site #120 | Whittier90602 | NCT07290036 | Map |
| CA | UCB Biopharma SRL Investigator Site #128 | Whittier90602 | NCT07290036 | Map |
| CO | UCB Biopharma SRL Investigator Site #123 | Fort Collins80528 | NCT07290036 | Map |
| DC | UCB Biopharma SRL Investigator Site #50707 | Washington D.C.20010 | NCT06921850 | Map |
| FL | UCB Biopharma SRL Investigator Site #50199 | Miami33136 | NCT06921850 | Map |
| FL | UCB Biopharma SRL Investigator Site #143 | Ormond Beach32174 | NCT07290036 | Map |
| FL | UCB Biopharma SRL Investigator Site #113 | South Miami33155 | NCT07290036 | Map |
| FL | UCB Biopharma SRL Investigator Site #103 | South Miami33155 | NCT06888193 | Map |
| IL | UCB Biopharma SRL Investigator Site #132 | Chicago60661 | NCT07290036 | Map |
| MI | UCB Biopharma SRL Investigator Site #50178 | Clarkston48346 | NCT06921850 | Map |
| MI | UCB Biopharma SRL Investigator Site #50710 | Fort Gratiot48059 | NCT06921850 | — |
| MI | UCB Biopharma SRL Investigator Site #134 | Lansing48911 | NCT07290036 | Map |
| MI | UCB Biopharma SRL Investigator Site #50711 | Troy48084 | NCT06921850 | Map |
| NJ | UCB Biopharma SRL Investigator Site #140 | West Long Branch07764-1503 | NCT07290036 | Map |
| NM | UCB Biopharma SRL Investigator Site #131 | Albuquerque87102 | NCT07290036 | Map |
| NY | UCB Biopharma SRL Investigator Site #50712 | New York10023 | NCT06921850 | Map |
| NC | UCB Biopharma SRL Investigator Site #50706 | Chapel Hill27516 | NCT06921850 | Map |
| NC | UCB Biopharma SRL Investigator Site #102 | Durham27710 | NCT06888193 | Map |
| OH | UCB Biopharma SRL Investigator Site #50745 | Columbus43213 | NCT07219420 | Map |
| OH | UCB Biopharma SRL Investigator Site #50202 | Fairborn45324 | NCT06921850 | Map |
| OH | UCB Biopharma SRL Investigator Site #144 | Vandalia45377 | NCT07290036 | Map |
| PA | UCB Biopharma SRL Investigator Site #115 | Duncansville16635 | NCT07290036 | Map |
| SC | UCB Biopharma SRL Investigator Site #142 | Rock Hill29732 | NCT07290036 | Map |
| TN | UCB Biopharma SRL Investigator Site #116 | Jackson38305 | NCT07290036 | Map |
| TN | UCB Biopharma SRL Investigator Site #138 | Murfreesboro37128 | NCT07290036 | Map |
| TX | UCB Biopharma SRL Investigator Site #50201 | Arlington76011 | NCT06921850 | Map |
| TX | UCB Biopharma SRL Investigator Site #129 | Baytown77521 | NCT07290036 | Map |
| TX | UCB Biopharma SRL Investigator Site #136 | Colleyville76034 | NCT07290036 | Map |
| TX | UCB Biopharma SRL Investigator Site #135 | Mesquite75150 | NCT07290036 | Map |
| TX | UCB Biopharma SRL Investigator Site #124 | Plano75075 | NCT07290036 | Map |
| WA | UCB Biopharma SRL Investigator Site #121 | Bellevue98004 | NCT07290036 | Map |
| WA | UCB Biopharma SRL Investigator Site #145 | Spokane99216 | NCT07290036 | Map |
| WV | UCB Biopharma SRL Investigator Site #130 | Beckley25801 | NCT07290036 | Map |
| WI | UCB Biopharma SRL Investigator Site #101 | Milwaukee53226 | NCT06888193 | Map |
Bimekizumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | Total |
|---|---|---|---|---|---|---|---|
| P1 | 2 | 4 | 1 | 7 | |||
| P2 | 1 | 12 | 1 | 14 | |||
| P3 | 4 | 4 | 16 | 24 | |||
| P4 | 2 | 1 | 2 | 5 | |||
| N/A | 1 | 1 |
Recruiting Bimekizumab clinical trials (11)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06425549 | BE TOGETHERA Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis | P3 | Moderate to Severe Plaque Psoriasis | 168 | Jun 2024 |
| NCT06668181 | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | P3 | Enthesitis-related Arthritis | 40 | Mar 2025 |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | Psoriasis | 10 | Aug 2026 |
| NCT07219420 | BeSeenA Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis | P3 | Palmoplantar Pustulosis | 320 | Nov 2025 |
| NCT06921850 | A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | P3 | Hidradenitis Suppurativa | 40 | Apr 2025 |
| NCT06742333 | EARLYPSOEarly Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? | P2 | Psoriasis | 40 | Jul 2025 |
| NCT07290036 | A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | P1 | Psoriatic Arthritis | 392 | Dec 2025 |
| NCT07497620 | Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP | P4 | Pityriasis Rubra Pilaris | 12 | Jul 2026 |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | Rheumatic Disease | 80 | Sep 2025 |
| NCT06888193 | BE CARINGA Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) | P1 | Moderate to Severe Plaque Psoriasis | 20 | Nov 2025 |
| NCT06786936 | ELATEEvaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms | — | Psoriatic Arthritis | 50 | Jun 2025 |
Bimekizumab clinical trials by indication
Chronic Plaque Psoriasis (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06011733 | BE SHINING | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis |
| NCT03598790 | BE BRIGHT | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03536884 | BE RADIANT | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03766685 | PSO | P3 | completed | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) |
| NCT03412747 | BE SURE | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03410992 | BE READY | P3 | completed | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03370133 | BE VIVID | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03230292 | — | P2 | completed | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis |
| + 3 more, see All trials below. | ||||
Psoriatic Arthritis (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07290036 | — | P1 | recruiting | A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults |
| NCT06786936 | ELATE | N/A | recruiting | Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms |
| NCT06624228 | — | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis |
| NCT04009499 | BE VITAL | P3 | completed | A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
| NCT03895203 | BE OPTIMAL | P3 | completed | A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
| NCT03896581 | BE COMPLETE | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
| NCT04109976 | — | P3 | completed | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis |
| NCT03347110 | BE ACTIVE 2 | P2 | completed | A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis |
| + 1 more, see All trials below. | ||||
Moderate to Severe Plaque Psoriasis (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06425549 | BE TOGETHER | P3 | recruiting | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis |
| NCT06506916 | BE UNIQUE | P3 | active not recruiting | A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis |
| NCT06888193 | BE CARING | P1 | recruiting | A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) |
| NCT04718896 | BE CONNECTED | P2 | completed | A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis |
| NCT05020249 | — | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis |
Hidradenitis Suppurativa (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06921850 | — | P3 | recruiting | A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa |
| NCT04901195 | BE HEARD EXT | P3 | active not recruiting | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT04242446 | BE HEARD I | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT04242498 | BE HEARD II | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT03248531 | — | P2 | completed | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. |
Ankylosing Spondylitis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03355573 | BE AGILE 2 | P2 | completed | A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis |
| NCT03928743 | BE MOBILE 2 | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
| NCT03215277 | — | P2 | completed | A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis |
| NCT02963506 | BE AGILE | P2 | completed | A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
Psoriasis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07352566 | — | P4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT06742333 | EARLYPSO | P2 | recruiting | Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? |
| NCT04340076 | BeNeBio | P4 | completed | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis |
Healthy Volunteers (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03895385 | — | P1 | completed | A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects |
| NCT03707717 | — | P1 | completed | A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants |
| NCT05028127 | — | P1 | completed | A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects |
Healthy Study Participants (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05292131 | — | P1 | completed | A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants |
| NCT04255862 | — | P1 | terminated | A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants |
Pityriasis Rubra Pilaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07497620 | — | P4 | not yet recruiting | Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP |
Palmoplantar Pustulosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07219420 | BeSeen | P3 | recruiting | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis |
Rheumatic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07138898 | — | P2 | not yet recruiting | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
Enthesitis-related Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06668181 | — | P3 | recruiting | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
Plaque Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06336343 | — | P4 | completed | Bimekizumab in Plaque Psoriasis |
Psoriasis Vulgaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05499416 | — | P4 | withdrawn | Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis |
Axial Spondyloarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04436640 | BE MOVING | P3 | active not recruiting | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis |
Nonradiographic Axial Spondyloarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03928704 | BE MOBILE 1 | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis |
Rheumatoid Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02430909 | — | P2 | completed | Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis |
Bimekizumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BeNeBio | NCT04340076 | P4 | completed | Psoriasis | 244 | PMID 34656148 |
| BE TOGETHER | NCT06425549 | P3 | recruiting | Moderate to Severe Plaque Psoriasis | 168 | — |
| BeSeen | NCT07219420 | P3 | recruiting | Palmoplantar Pustulosis | 320 | — |
| BE UNIQUE | NCT06506916 | P3 | active not recruiting | Moderate to Severe Plaque Psoriasis | 89 | — |
| BE MOVING | NCT04436640 | P3 | active not recruiting | Axial Spondyloarthritis | 508 | PMID 41125403 |
| BE HEARD EXT | NCT04901195 | P3 | active not recruiting | Hidradenitis Suppurativa | 658 | PMID 40524676 |
| BE VITAL | NCT04009499 | P3 | completed | Psoriatic Arthritis | 1,131 | PMID 41381988 |
| BE SHINING | NCT06011733 | P3 | completed | Chronic Plaque Psoriasis | 133 | — |
| BE BRIGHT | NCT03598790 | P3 | completed | Chronic Plaque Psoriasis | 1,353 | PMID 36689515 |
| BE RADIANT | NCT03536884 | P3 | completed | Chronic Plaque Psoriasis | 743 | PMID 37182701 |
| BE MOBILE 1 | NCT03928704 | P3 | completed | Nonradiographic Axial Spondyloarthritis | 274 | PMID 36649967 |
| BE HEARD I | NCT04242446 | P3 | completed | Hidradenitis Suppurativa | 505 | PMID 40652434 |
| BE HEARD II | NCT04242498 | P3 | completed | Hidradenitis Suppurativa | 509 | PMID 41689425 |
| BE MOBILE 2 | NCT03928743 | P3 | completed | Ankylosing Spondylitis | 332 | PMID 38599650 |
| BE OPTIMAL | NCT03895203 | P3 | completed | Psoriatic Arthritis | 852 | PMID 37696588 |
| BE COMPLETE | NCT03896581 | P3 | completed | Psoriatic Arthritis | 400 | PMID 38488975 |
| PSO | NCT03766685 | P3 | completed | Chronic Plaque Psoriasis | 172 | PMID 40156698 |
| BE SURE | NCT03412747 | P3 | completed | Chronic Plaque Psoriasis | 478 | PMID 33891379 |
| BE READY | NCT03410992 | P3 | completed | Chronic Plaque Psoriasis | 435 | PMID 41359217 |
| BE VIVID | NCT03370133 | P3 | completed | Chronic Plaque Psoriasis | 567 | PMID 41580158 |
| EARLYPSO | NCT06742333 | P2 | recruiting | Psoriasis | 40 | — |
| BE CONNECTED | NCT04718896 | P2 | completed | Moderate to Severe Plaque Psoriasis | 41 | — |
| BE AGILE 2 | NCT03355573 | P2 | completed | Ankylosing Spondylitis | 255 | PMID 35829672 |
| BE ACTIVE 2 | NCT03347110 | P2 | completed | Psoriatic Arthritis | 184 | PMID 35789257 |
| BE ABLE 2 | NCT03010527 | P2 | completed | Chronic Plaque Psoriasis | 217 | PMID 32473974 |
| BE AGILE | NCT02963506 | P2 | completed | Ankylosing Spondylitis | 303 | PMID 32253184 |
| BE ACTIVE | NCT02969525 | P2 | completed | Psoriatic Arthritis | 206 | PMID 32035552 |
| PK | NCT03025542 | P2 | completed | Chronic Plaque Psoriasis | 49 | PMID 34687214 |
| BE ABLE 1 | NCT02905006 | P2 | completed | Chronic Plaque Psoriasis | 250 | PMID 35544084 |
Terminated and withdrawn Bimekizumab trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05499416withdrawnEffect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
- NCT04255862terminatedA Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
All Bimekizumab trials (51)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06425549 | BE TOGETHER | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis | P3 | recruiting | 168 | UCB Biopharma SRL | Jun 2024 |
| NCT06668181 | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | P3 | recruiting | 40 | UCB Biopharma SRL | Mar 2025 | |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | not yet recruiting | 10 | University of California, San Francisco | Aug 2026 | |
| NCT07219420 | BeSeen | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis | P3 | recruiting | 320 | UCB Biopharma SRL | Nov 2025 |
| NCT06921850 | A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | P3 | recruiting | 40 | UCB Biopharma SRL | Apr 2025 | |
| NCT06742333 | EARLYPSO | Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? | P2 | recruiting | 40 | Centre Hospitalier Universitaire de Nice | Jul 2025 |
| NCT07290036 | A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | P1 | recruiting | 392 | UCB Biopharma SRL | Dec 2025 | |
| NCT06506916 | BE UNIQUE | A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | P3 | active not recruiting | 89 | UCB Biopharma SRL | Jul 2024 |
| NCT07497620 | Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP | P4 | not yet recruiting | 12 | Mayo Clinic | Jul 2026 | |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | not yet recruiting | 80 | NYU Langone Health | Sep 2025 | |
| NCT06888193 | BE CARING | A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) | P1 | recruiting | 20 | UCB Biopharma SRL | Nov 2025 |
| NCT06786936 | ELATE | Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms | — | recruiting | 50 | NHS Greater Glasgow and Clyde | Jun 2025 |
| NCT04436640 | BE MOVING | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis | P3 | active not recruiting | 508 | UCB Biopharma SRL | Jun 2020 |
| NCT04901195 | BE HEARD EXT | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | P3 | active not recruiting | 658 | UCB Biopharma SRL | May 2021 |
| NCT06624228 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis | P3 | active not recruiting | 684 | UCB Biopharma SRL | Oct 2024 | |
| NCT04009499 | BE VITAL | A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | P3 | completed | 1,131 | UCB Biopharma SRL | Aug 2019 |
| NCT06336343 | Bimekizumab in Plaque Psoriasis | P4 | completed | 60 | Icahn School of Medicine at Mount Sinai | Jun 2024 | |
| NCT04718896 | BE CONNECTED | A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis | P2 | completed | 41 | UCB Biopharma SRL | Apr 2021 |
| NCT06011733 | BE SHINING | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis | P3 | completed | 133 | UCB Biopharma SRL | Oct 2023 |
| NCT04340076 | BeNeBio | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | P4 | completed | 244 | Radboud University Medical Center | Aug 2020 |
| NCT05499416 | Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis | P4 | withdrawn | 0 | Innovaderm Research Inc. | Jan 2023 | |
| NCT03598790 | BE BRIGHT | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | P3 | completed | 1,353 | UCB Biopharma SRL | Sep 2018 |
| NCT03536884 | BE RADIANT | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | P3 | completed | 743 | UCB Biopharma SRL | Jun 2018 |
| NCT03928704 | BE MOBILE 1 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis | P3 | completed | 274 | UCB Biopharma SRL | Apr 2019 |
| NCT04242446 | BE HEARD I | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | P3 | completed | 505 | UCB Biopharma SRL | Feb 2020 |
| NCT05292131 | A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants | P1 | completed | 121 | UCB Biopharma SRL | Mar 2022 | |
| NCT03355573 | BE AGILE 2 | A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis | P2 | completed | 255 | UCB Biopharma SRL | Nov 2017 |
| NCT04242498 | BE HEARD II | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | P3 | completed | 509 | UCB Biopharma SRL | Mar 2020 |
| NCT05020249 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis | P3 | completed | 47 | UCB Biopharma SRL | Sep 2021 | |
| NCT03928743 | BE MOBILE 2 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis | P3 | completed | 332 | UCB Biopharma SRL | Apr 2019 |
| NCT03895203 | BE OPTIMAL | A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | P3 | completed | 852 | UCB Biopharma SRL | Apr 2019 |
| NCT03896581 | BE COMPLETE | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | P3 | completed | 400 | UCB Biopharma SRL | Mar 2019 |
| NCT04255862 | A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants | P1 | terminated | 71 | UCB Biopharma SRL | Feb 2020 | |
| NCT04109976 | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis | P3 | completed | 214 | UCB Biopharma SRL | Aug 2019 | |
| NCT03347110 | BE ACTIVE 2 | A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis | P2 | completed | 184 | UCB Biopharma SRL | Nov 2017 |
| NCT03766685 | PSO | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) | P3 | completed | 172 | UCB Biopharma SRL | Dec 2018 |
| NCT03215277 | A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis | P2 | completed | 76 | UCB Biopharma SRL | Oct 2017 | |
| NCT03412747 | BE SURE | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | P3 | completed | 478 | UCB Biopharma SRL | Jan 2018 |
| NCT03410992 | BE READY | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | P3 | completed | 435 | UCB Biopharma SRL | Feb 2018 |
| NCT03370133 | BE VIVID | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | P3 | completed | 567 | UCB Biopharma SRL | Dec 2017 |
| NCT03895385 | A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects | P1 | completed | 56 | UCB Biopharma S.P.R.L. | Apr 2019 | |
| NCT03707717 | A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants | P1 | completed | 189 | UCB Biopharma S.P.R.L. | Oct 2018 | |
| NCT03230292 | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis | P2 | completed | 43 | UCB Biopharma SRL | Jul 2017 | |
| NCT03248531 | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. | P2 | completed | 90 | UCB Biopharma SRL | Sep 2017 | |
| NCT03010527 | BE ABLE 2 | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis | P2 | completed | 217 | UCB Biopharma SRL | Dec 2016 |
| NCT02963506 | BE AGILE | A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis | P2 | completed | 303 | UCB Biopharma S.P.R.L. | Oct 2016 |
| NCT02969525 | BE ACTIVE | A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis | P2 | completed | 206 | UCB Biopharma S.P.R.L. | Oct 2016 |
| NCT03025542 | PK | A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis | P2 | completed | 49 | UCB Biopharma SRL | Dec 2016 |
| NCT02905006 | BE ABLE 1 | Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis | P2 | completed | 250 | UCB Biopharma S.P.R.L. | Aug 2016 |
| NCT02430909 | Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis | P2 | completed | 159 | UCB Celltech | Apr 2015 | |
| NCT05028127 | A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects | P1 | completed | 12 | UCB Celltech | Mar 2016 |
Bimekizumab clinical trials: frequently asked questions
- How many Bimekizumab clinical trials are there?
- 51 Bimekizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 8 are actively recruiting participants. 34 are marked completed.
- Are Bimekizumab clinical trials recruiting in 2026?
- Yes — 8 Bimekizumab trials are actively recruiting in 2026, with 44 U.S. sites across 19 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Bimekizumab being studied for?
- Bimekizumab is being studied for Psoriatic Arthritis, Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Hidradenitis Suppurativa, Moderate to Severe Plaque Psoriasis and 20 more. The trials are grouped by indication on this page.
- What phase is Bimekizumab in?
- Bimekizumab clinical trials span 5 Phase 4, 24 Phase 3, 14 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Bimekizumab clinical trials?
- The lead sponsor across the most Bimekizumab trials is UCB Biopharma SRL, with 10 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Bimekizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: